134 related articles for article (PubMed ID: 38588788)
1. Diagnostic value of isolated plasma biomarkers and its combination in neurodegenerative dementias: A multicenter cohort study.
Chen Y; Wang Y; Tao Q; Lu P; Meng F; Zhuang L; Qiao S; Zhang Y; Luo B; Liu Y; Peng G
Clin Chim Acta; 2024 May; 558():118784. PubMed ID: 38588788
[TBL] [Abstract][Full Text] [Related]
2. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy.
Chouliaras L; Thomas A; Malpetti M; Donaghy P; Kane J; Mak E; Savulich G; Prats-Sedano MA; Heslegrave AJ; Zetterberg H; Su L; Rowe JB; O'Brien JT
J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):651-658. PubMed ID: 35078917
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
[TBL] [Abstract][Full Text] [Related]
4. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
Bolsewig K; van Unnik AAJM; Blujdea ER; Gonzalez MC; Ashton NJ; Aarsland D; Zetterberg H; Padovani A; Bonanni L; Mollenhauer B; Schade S; Vandenberghe R; Poesen K; Kramberger MG; Paquet C; Bousiges O; Cretin B; Willemse EAJ; Teunissen CE; Lemstra AW;
Neurology; 2024 Jun; 102(12):e209418. PubMed ID: 38830138
[TBL] [Abstract][Full Text] [Related]
5. Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease.
Cousins KAQ; Phillips JS; Das SR; O'Brien K; Tropea TF; Chen-Plotkin A; Shaw LM; Nasrallah IM; Mechanic-Hamilton D; McMillan CT; Irwin DJ; Lee EB; Wolk DA
Alzheimers Dement; 2024 Jun; 20(6):3889-3905. PubMed ID: 38644682
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort.
Sarto J; Ruiz-García R; Guillén N; Ramos-Campoy Ó; Falgàs N; Esteller D; Contador J; Fernández G; González Y; Tort-Merino A; Juncà-Parella J; Bosch B; Borrego-Écija S; Molina-Porcel L; Castellví M; Vergara M; Antonell A; Augé JM; Naranjo L; Sanchez-Valle R; Lladó A; Balasa M
Neurology; 2023 Feb; 100(8):e860-e873. PubMed ID: 36450604
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and Prognostic Value of Plasma GFAP in Sporadic Creutzfeldt-Jakob Disease in the Clinical Setting of Rapidly Progressive Dementia.
Bentivenga GM; Baiardi S; Mastrangelo A; Zenesini C; Mammana A; Rossi M; Polischi B; Capellari S; Parchi P
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791145
[TBL] [Abstract][Full Text] [Related]
8. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias.
Bolsewig K; Hok-A-Hin YS; Sepe FN; Boonkamp L; Jacobs D; Bellomo G; Paoletti FP; Vanmechelen E; Teunissen CE; Parnetti L; Willemse EAJ
J Alzheimers Dis; 2022; 90(1):363-380. PubMed ID: 36120776
[TBL] [Abstract][Full Text] [Related]
9. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
10. Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers.
Orduña Dolado A; Stomrud E; Ashton NJ; Nilsson J; Quijano-Rubio C; Jethwa A; Brum WS; Brinkmalm Westman A; Zetterberg H; Blennow K; Janelidze S; Hansson O
Alzheimers Res Ther; 2024 Jun; 16(1):132. PubMed ID: 38909218
[TBL] [Abstract][Full Text] [Related]
11. Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study.
Zhang Y; Ferreira PCL; Jacobsen E; Bellaver B; Pascoal TA; Snitz BE; Chang CH; Villemagne VL; Ganguli M; Karikari TK
Alzheimers Dement; 2024 Jun; 20(6):4199-4211. PubMed ID: 38753951
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity.
Honig LS; Kang MS; Lee AJ; Reyes-Dumeyer D; Piriz A; Soriano B; Franco Y; Coronado ZD; Recio P; Mejía DR; Medrano M; Lantigua RA; Teich AF; Dage JL; Mayeux R
JAMA Netw Open; 2023 Apr; 6(4):e238214. PubMed ID: 37079306
[TBL] [Abstract][Full Text] [Related]
13. The dynamics of plasma biomarkers across the Alzheimer's continuum.
Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT
Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
[TBL] [Abstract][Full Text] [Related]
15. Plasma biomarkers for predicting the development of dementia in a community-dwelling older Japanese population.
Ohara T; Tatebe H; Hata J; Honda T; Shibata M; Matsuura S; Mikami T; Maeda T; Ono K; Mimura M; Nakashima K; Iga JI; Takebayashi M; Tokuda T; Ninomiya T;
Psychiatry Clin Neurosci; 2024 Jun; 78(6):362-371. PubMed ID: 38606661
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
[TBL] [Abstract][Full Text] [Related]
17. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
[TBL] [Abstract][Full Text] [Related]
18. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
[TBL] [Abstract][Full Text] [Related]
19. Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer's disease and frontotemporal lobar degeneration.
Benussi A; Cantoni V; Rivolta J; Archetti S; Micheli A; Ashton N; Zetterberg H; Blennow K; Borroni B
Alzheimers Res Ther; 2022 Oct; 14(1):155. PubMed ID: 36229847
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia.
Marelli C; Hourregue C; Gutierrez LA; Paquet C; Menjot de Champfleur N; De Verbizier D; Jacob M; Dubois J; Maleska AM; Hirtz C; Navucet S; Bennys K; Dumurgier J; Cognat E; Berr C; Magnin E; Lehmann S; Gabelle A
J Alzheimers Dis; 2020; 74(3):903-911. PubMed ID: 32083577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
